This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
NIHR HSRIC. Abatacept for psoriatic arthritis – second line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015
Psoriatic arthritis occurs when the joints are affected in people who already have psoriasis (a skin condition that causes itchy red, flaky, scaly patches of skin). People with psoriatic arthritis often feel pain and experience stiffness in joints, for example, in the hands, feet, knees, neck, spine and elbows.
Abatacept is a new drug for the treatment of psoriatic arthritis which is injected under skin. Studies are currently underway to see how well the drug works and whether it is safe to use in patients with the condition.
If abatacept is licensed for use in the UK, it could offer a new treatment option for patients with psoriatic arthritis to reduce disability when current treatments have not worked.
Subject indexing assigned by CRD
Abatacept; Antirheumatic Agents; Arthritis, Psoriatic; Humans; Immunoconjugates
Country of organisation
An English language summary is available.
Address for correspondence
NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: firstname.lastname@example.org
Date abstract record published